Page 113 - MemoriaEHD-Eng

www.ciberehd.org

• g N, M a, C D, M á, g L, p p .. Randomized trial com-
Most relevant uañaBeNsoNegaLerDáuxíiFreeriset aL
paring monthly ibandronate and weekly alendronate for osteoporosis in patients
scientific with primary biliary cirrhosis.Hepatology. 2013 Dec;58(6):2070-8.

articles
• Bañares r, NeveNs F, LarseN Fs, JaLaN r, aLBiLLos a, DoLLiNger M. Extracorporeal albumin
dialysis with the molecular adsorbent recirculating system in acute-on-chronic liver

failure: the RELIEF trial.Hepatology. 2013 Mar;57(3):1153-62.

• Liu Jz, hov Jr, FoLseraas t, eLLiNghaus e, rushBrooK sM, DoNCheva Nt et aL.. Dense ge-
notyping of immune-related disease regions identifies nine new risk loci for primary

sclerosing cholangitis.Nat Genet. 2013 Jun;45(6):670-5.

• DuBreuiL M, ruiz-gaspà s, guañaBeNs N, peris p, aLvarez L, MoNegaL a et aL.. Ursodeoxy-
cholic acid increases differentiation and mineralization and neutralizes the damaging

effects of bilirubin on osteoblastic cells.Liver Int. 2013 Aug;33(7):1029-38.

• MartíNez-Ferrer a, BLasCo J, CarrasCo JL, MaCho JM, roMáN Ls, López a et aL.. Risk factors
for the development of vertebral fractures after percutaneous vertebroplasty.J Bone

Miner Res. 2013 Aug;28(8):1821-9.

Highlights
The group has launched a new research project aimed at knowing the metabolo-
mic profile of pruritus of cholestasis, and continues with the project that assesses

the role of bile acids and bilirubin as well as the protective effect of ursodeoxy-

cholic acid in the pathogenesis of osteoporosis in cholestatic diseases. As specific
achievements has presented the main results in the domestic and international

congresses of Hepatology and Metabolic Bone Diseases. The team has conti-

nued collaborating with other groups CIBERehd, and with international groups
on cholestatic diseases, specifically the Global PBC study group and the IPSCSG.

Likewise the team has been invited to take part into the International Autoimmune
Hepatitis group. Regarding outputs the group has published articles identifying

new genes involved in the pathogenesis of primary sclerosing cholangitis, and

the protective role of ursodeoxycholic acid on the harmful effects of bile acids
and bilirubin in model human osteoblasts in culture. A clinical trial comparing the

effects of alendronate and monthly ibandronate for the treatment of osteoporosis

in primary biliary cirrhosis has been published, showing that both regimens are
safe and increase bone mass after two years of treatment. Another paper defined

the risk factors for presenting new fractures in osteoporotic patients treated with
vertebroplasty. In cooperation with other CIBERehd groups, a trial assessing the

effect of albumin dialysis in patients with decompensated liver cirrhosis compared

with standard therapy has been published. Two of these papers are especially im-
portant since they have been accompanied by an editorial. Other aspects to point

out are the invitation of members of the team to give lectures in international

courses and symposia, as well as the appointment as associate editor for Bone, a 13
journal specialized in metabolic bone diseases.
20
T
OR
P
RE
L
A
NU
N
A
D /
H
E
ER
IB
C

113